The current state of stem cell therapy for ocular disease

Samantha Bobba, Nick Di Girolamo, Megan Munsie, Fred Chen, Alice Pébay, Damien Harkin, Alex Hewitt, Michael O'Connor, Samuel McLenachan, Audra M.A. Shadforth, Stephanie L. Watson

Research output: Contribution to journalReview articlepeer-review

11 Citations (Scopus)

Abstract

Herein, we review the safety, efficacy, regulatory standards and ethical implications of the use of stem cells in ocular disease. A literature review was conducted, registered clinical trials reviewed, and expert opinions sought. Guidelines and codes of conduct from international societies and professional bodies were also reviewed. Collated data is presented on current progress in the field of ocular regenerative medicine, future challenges, the clinical trial process and ethical considerations in stem cell therapy. A greater understanding of the function and location of ocular stem cells has led to rapid advances in possible therapeutic applications. However, in the context of significant technical challenges and potential long-term complications, it is imperative that stem cell practices operate within formal clinical trial frameworks. While there remains broad scope for innovation, ongoing evidence-based review of potential interventions and the development of standardized protocols are necessary to ensure patient safety and best practice in ophthalmic care.

Original languageEnglish
Pages (from-to)65-75
Number of pages11
JournalExperimental Eye Research
Volume177
DOIs
Publication statusPublished - 1 Dec 2018

Fingerprint

Dive into the research topics of 'The current state of stem cell therapy for ocular disease'. Together they form a unique fingerprint.

Cite this